Study on Mastocytosis for Rupatadine Treatment

NCT ID: NCT01481909

Last Updated: 2016-11-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2/PHASE3
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-09-30
• Study Completion Date: 2011-11-30

Brief Summary

Study title:

An exploratory, randomised, double-blind, placebo controlled crossover study to assess the efficacy of 20 mg Rupatadine on the treatment of mastocytosis symptoms.

Study code:

SMART-2010-1 Principal Investigator, Co-Investigator, sponsor, and study centre (acc. to § 40 Abs. 4 AMG) Dr. med. F. Siebenhaar, Prof. Dr. Med. M. Maurer, Allergie-Centrum-Charité, Department of Dermatology and Allergy, Charité - Universitätsmedizin Berlin, Charitéplatz 1, D-10117 Berlin Biometry and biostatistical analyses Division of Biostatistics and Clinical Epidemiology, Charité - Universitätsmedizin Berlin, Charitéplatz 1, D-10117 Berlin Monitoring Coordination Centre for Clinical Studies (KKS), Charité - Universitätsmedizin Berlin, Charitéplatz 1, D-10117 Berlin Clinical phase Phase II

Primary objective:

Reduction of wheal and flare type skin reaction after standardised provocation testing assessed by volumetric and thermographic measurements.

Secondary objectives:

Improvement of additional related symptoms (e.g. pruritus) and subjective affliction as assessed by symptom score, DLQI, Itchy-QoL and VAS.

Study design:

An exploratory, randomised, double-blind, placebo controlled crossover study

Type and number of patients:

Male and female patients (n = 30) with cutaneous mastocytosis and indolent systemic mastocytosis with skin involvement

Main criteria for inclusion:

Mastocytosis patients aged 18-65 years, signed written consent, no systemic corticosteroid or other immunosuppressive therapy, no permanent severe diseases Test product, dose and mode of administration 20 mg Rupatadine or placebo before provocation testing, oral administration (tablets)

Duration of treatment:

28 days (testing will be done at the day of last treatment)

Assessment of efficacy:

1. Assessment of wheal and flare development by planimetric analyses of digital photographic, volumetric, and thermographic imaging (time lapse) before and after treatment with study medication,

2. Additional assessment of symptoms,

3. Assessment of life quality

Main criteria of evaluation:

Efficacy

Conditions

Mastocytosis

Keywords

Assessment of wheal and flare development; Assessment of life quality

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Sugar Pill

All patients included in this study will be subjected at the screening visit to a standardized provocation of Darier's sign by a device for standardized provocation testing (Hartmann and Siebenhaar 2009). Patients that exhibit positive skin test reactions will be enrolled, provided that they meet all inclusion criteria and none of the exclusion criteria and that they give informed consent. Study patients will receive treatment for 28 days (minimal 25, maximal 30 days) before visit 1 and visit 2 including the same day before the provocation test (RUP 20mg/day or placebo according to randomization). All patients will receive antihistaminic rescue medication immediately after completing the testing when necessary.

Group Type: PLACEBO_COMPARATOR

Rupatadin

Intervention Type: DRUG

20 mg, 28 days over 60 days

Rupafin

All patients included in this study will be subjected at the screening visit to a standardized provocation of Darier's sign by a device for standardized provocation testing (Hartmann and Siebenhaar 2009). Patients that exhibit positive skin test reactions will be enrolled, provided that they meet all inclusion criteria and none of the exclusion criteria and that they give informed consent. Study patients will receive treatment for 28 days (minimal 25, maximal 30 days) before visit 1 and visit 2 including the same day before the provocation test (RUP 20mg/day or placebo according to randomization). All patients will receive antihistaminic rescue medication immediately after completing the testing when necessary.

Group Type: ACTIVE_COMPARATOR

Rupatadin

Intervention Type: DRUG

20 mg, 28 days over 60 days

Interventions

Rupatadin

20 mg, 28 days over 60 days

Intervention Type: DRUG

Other Intervention Names

Each tablet contains 10 mg RUP

Eligibility Criteria

Inclusion Criteria

1. Chronic stable symptomatic maculopapulous cutaneous mastocytosis or indolent systemic mastocytosis with skin involvement and a positive Darier's Sign

2. Age between 18 and 65 years.

3. Female patients must be using a highly effective method of birth control (such as implants, injectables, combined oral contraceptives, some IUDs, sexual abstinence, vasectomised partner), or they must be postmenopausal, surgically sterilised, or hysterectomised.

4. Voluntarily signed written informed consent.

Exclusion Criteria

1. The presence of permanent severe diseases, especially those affecting the immune system, except for mastocytosis

2. History or presence of epilepsy, significant neurological disorders, cerebrovascular attacks or ischemia

3. History or presence of myocardial infarction or cardiac arrhythmia which requires drug therapy, hyper-/hypokalemia, bradycardia < 50bpm, QTc interval > 440ms

4. Evidence of severe renal dysfunction (creatinine > 1,5 x upper reference value)

5. Evidence of significant hepatic disease (liver enzymes > 2 x upper reference value)

6. History of adverse reactions to RUP, or other ingredients of the IMP

7. Presence of active cancer which requires chemotherapy or radiation therapy

8. Aggressive systemic mastocytosis

9. History or presence of alcohol abuse or drug addiction

10. Participation in any clinical trial within 4 weeks prior to enrolment

11. Commitment to an institution in terms of § 40 Abs. 1 S. 3 Nr. 4 AMG

12. Intake of antihistamines or leukotriene antagonists within 7 days prior to the beginning of the study

13. Intake of oral corticosteroids within 14 days prior to the beginning of the study

14. Use of depot corticosteroids or chronic systemic corticosteroids within 21 days before beginning of the study

15. Pregnancy or breast-feeding

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Marcus Maurer

OTHER

Sponsor Role: lead

Responsible Party

Marcus Maurer

Professor

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Marcus Maurer, MD

Role: PRINCIPAL_INVESTIGATOR

University Berlin Charitè

Locations

University Charité

Berlin, Germany, Germany

Countries

Germany

Other Identifiers

SMART-2010-1

Identifier Type: -

Identifier Source: org_study_id